COMPANY PROFILE

OpGen

Explore full profile

Microbial Genetic Analysis - OpGenOpGen

Gaithersburg, United StatesFounded 2002Biotech & Life Sciences

Valuation $254M Market cap · 2026

Revenue $1.3M Latest reported FY

EBITDA $24M Latest reported FY

About OpGen

OpGen, Inc. (NASDAQ: OPGN) operates as a precision medicine company, developing molecular diagnostic solutions to address the global threat of antimicrobial resistance (AMR). Founded in 2002 and headquartered in Rockville, Maryland, the company's business model centers on providing rapid, actionable information to clinicians for managing life-threatening infectious diseases.

A pivotal moment in the company's history was the business combination with Curetis N.V., a German molecular diagnostics firm, which closed on April 1, 2020. This merger significantly expanded OpGen's portfolio, creating a transatlantic entity by integrating Curetis' Unyvero platform and the ARES AMR database with OpGen's own diagnostic and bioinformatics technologies. The transaction aimed to create synergies in technology and commercialization, combining sales teams in the US and Europe to market a complementary product suite. Following the merger, Oliver Schacht, former CEO of Curetis, was appointed President and CEO of the combined company.

OpGen's revenue is generated from the sale of its diagnostic products, laboratory services, and through collaborations. The company serves healthcare settings, primarily hospitals, by offering tools to improve patient outcomes and support antibiotic stewardship. Its product lineup includes the Unyvero platform, a high-plex PCR system for diagnosing infectious diseases in hours, and the Acuitas AMR Gene Panel. The FDA-cleared Acuitas panel is a qualitative in vitro diagnostic test that uses real-time PCR to detect 28 genetic antimicrobial resistance markers from isolated bacterial colonies in approximately 2.5 hours. The company has also been developing the Unyvero Urinary Tract Infection (UTI) Panel. Additionally, through its subsidiary Ares Genetics, OpGen possesses the ARESdb, a comprehensive database on the genetics of antimicrobial resistance used for bioinformatics and AI-powered antibiotic response prediction.

Recent corporate filings indicate a significant strategic shift. In 2023, OpGen began a transition from precision medicine to focus on financial services and technology through a new subsidiary, CapForce International Holdings Ltd. This new venture offers listing sponsorship and consultancy services, marking a significant repositioning of the company's primary business model.

MoreLess Source: Dealroom company data

At a glance

Status: Listed
Founded: 2002
Headquarters: Gaithersburg, United States
Listing: IPO 2015
Employees: 44
Open positions: None listed
Dealroom signal: 69.6/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Testing, Analytics, Biotechnology, DNA, Genetics and genomics, Spinout, Biotech and Pharma, medical testing, DT and LS, science-based
Business model: Manufacturing
Client focus: b2b
Investment activity: 3 companies, latest May 2019
Capital deployed: $2.6M
Preferred round: ACQUISITION
Links: Website LinkedIn X

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

10 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
POST IPO EQUITY✓Other financing	Mar 2024	$3M	—	David Lazar	↗
POST IPO EQUITY✓Other financing	May 2023	$3.5M	—	Undisclosed	↗

Showing the latest 2 of 10 recorded eventsBook a demo for the full funding history →

Financials

Revenue, earnings and profit over time

Revenue, earnings and other financial measures where available. Years marked “E” are estimates.

Year	Revenue	Growth	EBITDA	Margin	Profit	Margin	R&D
2026	$1.3M	0%	$24M	1796.7%	$24M	1752.2%	$49K
2025	$1.3M	-16%	$24M	1796.7%	$24M	1752.2%	$49K
2024	$1.6M	-53%	$37K	2.3%	$12M	747.2%	$49K
2023	$3.4M	+31.1%	−$14M	-416.2%			$4.7M
2022	$2.6M	-39.5%	−$22M	-850.4%
2021	$4.3M	+2.2%	−$23M	-535.5%
2020	$4.2M	—	−$21M	-507.5%

Company filings, research estimates and Dealroom dataBook a demo for the full financial model →

Growth signals

OpGen website traffic

Latest recorded traffic for OpGen is 3.8K monthly website visits, down 5% over the last three months. OpGen's team declined 2.2% over the past year.

Latest monthly visits3.8K 3-month web change-5% 1-year team growth-2.2%

Monthly website visitsApr 2016–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
DGDeep GenomicsDeep Genomics is using artificial intelligence to build a new universe of life-saving genetic therapies	Toronto, Canada	Operational	112	$237M	$720M
INInivataClinical cancer genomics company harnessing the emerging potential of circulating DNA analysis	Morrisville, United States	Acquired
CGCofactor GenomicsCofactor Genomics uses RNA to diagnose disease	San Francisco, United States	Operational
DLDante LabsDante Labs is transforming genetics	New York City, United States	Operational
NHNew Horizon HealthResearches and develops technology for early-stage cancer screening	Hangzhou, China	Operational
QUQuetheraGene therapy company dedicated to improving the future treatment of common blinding eye diseases	Canterbury, United Kingdom	Acquired
STStilla TechnologiesBiotechnology company that focuses on accelerating the development of next-generation genetic tests	Villejuif, France	Acquired
PDPathogen DXDevelops a microarray based test specifically designed for the cannabis, botanical, food and agricultural testing markets	Scottsdale, United States	Operational